The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
The study will run across 18 sites and enroll roughly 200 patients over 24 months
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The plant is expected to enhance regional supply capabilities
The partnership also sets the stage for broader collaboration on rare disease treatments
Harbour BioMed brings advanced antibody discovery platforms to the table
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Subscribe To Our Newsletter & Stay Updated
